SUMMARY Cerebral blood flow has been measured using the non-invasive Xenon'33 clearance technique in eight normal subjects during an infusion of epoprostenol (prostacyclin, PGI2) at a dose of 5 ng/kg/min. The results were compared with a control infusion of saline given in a balanced order. PGI2 was found to result in a reduction in cerebral blood flow of about 8%. PGI2 also caused a small drop in diastolic blood pressure and it is proposed that the fall in cerebral blood flow may have been the result of disturbed autoregulation. The 
SUMMARY Cerebral blood flow has been measured using the non-invasive Xenon'33 clearance technique in eight normal subjects during an infusion of epoprostenol (prostacyclin, PGI2) at a dose of 5 ng/kg/min. The results were compared with a control infusion of saline given in a balanced order. PGI2 was found to result in a reduction in cerebral blood flow of about 8%. PGI2 also caused a small drop in diastolic blood pressure and it is proposed that the fall in cerebral blood flow may have been the result of disturbed autoregulation. The findings suggest that the therapeutic use of PGI2 in patients with cerebral artery spasm would not be accompanied by undesirable intracerebral steal.
It was proposed by Pickard and Mackenzie in 1973 ' that a vasodilatory endogenous prostaglandin with a rapid turnover was responsible for maintaining the normal level of cerebral blood flow. Epoprostenol (prostacyclin, PGI2) is the most suitable candidate for such a role. A product of arachidonic acid metabolism, it is formed in vascular endothelium,2 including that of cerebral vessels.34 It is a potent dilator of cerebral blood vessels in vitro356 and has been found to increase cerebral blood flow (CBF) in baboons when infused into the cartoid artery.' It has been suggested that PGI2 might have a therapeutic role in conditions associated with cerebral arterial spasm, such as subarachnoid haemorrhage.38 In addition to its vasodilatory properties, PGI2 is a potent inhibitor of platelet aggregation, and for this reason might also find application in a wider range of cerebrovascular conditions. We have therefore investigated the effects of exogenous PGI2 on CBF in normal human subjects. PGI, is rapidly broken down in the circulation and therefore has to be given by infusion.
Eight clinically normal subjects, four male and four female, with a mean age of 22 years (range 19-33) were studied. The study was approved by the Ethics Committee of the National Hospital, Queen Square and the subjects gave their informed consent. Each subject had two estimations of CBF separated by about 1 h. During one CBF measurement, the subject received a control infusion of 0 9% saline into an indwelling catheter in a forearm vein, and during the other measurement an infusion of PGI2 at a dose of 5 ng/kg/min. PGI2, synthesised by Upjohn and formulated by the Wellcome Foundation, was diluted in glycine buffer at pH 10 5 and given by constant infusion pump at a rate of 0 2 ml/min. This infusion was given for 10 min prior to the start of the CBF estimation, by which time other dynamic effects of PGI2 were apparent, and continued throughout the flow measurement. The order of treatments was balanced so that four subjects received PGI2 and four subjects saline as the first infusion. The infusions were not given blind, as we have found that characteristic facial flushing with PGI2 makes it obvious which treatment has been given. CBF was measured by the non-invasive intravenous Xenon'33 
Results
The results are presented in this table. Compared with the saline infusion, PGI2 resulted in small but significant reduction in mean CBF of 7-3 ml/lOOg/min (F fast) and 5*1 ml/lOOg/min (F initial). There was no significant change in PCV or arterial pCO2 that might have influenced the results. The pattern of end tidal Xe'33 concentration was not altered by the PGI2 infusion and it is therefore unlikely that there were alterations in the ratio of arterial to expired Xe concentrations that might have influenced the accuracy of the correction for arterial recirculation.
During the infusion of PGI2 all subjects developed a marked facial flush, a moderate tachycardia (mean rise in pulse rate = 12-3, p < 0-01) and a small fall in diastolic blood pressure (mean fall = 9 4 mmHg, p = < 0 01). Systolic blood pressure rose in five out of the eight subjects but the mean rise of 3-4 mmHg was not statistically significant. Four subjects complained of headache, and three others a slight heaviness in the head, 3 had palmar flushing and 1 suffered from nausea and restlessness.
Brown, Pickles
Discussion This study has demonstrated that, contrary to expectations, epoprostenol (prostacycin, PGI2) given intravenously results in a slight fall in mean CBF in normal subjects. Since completing our work another group has briefly reported similar findings in man using a dose of 4ng/kg/min.'0 The dose of 5 ng/kg/min used in the current study is the highest intravenous infusion rate than can be readily tolerated by conscious humans and even this dose is greatly in excess of normal circulating endogenous PGI2. '°The findings contrast with the effects of giving PGI2 in relatively enormous doses (5,000 ng/kg/min) directly into the carotid arteries of anaesthetised baboons, when an increase in CBF has been reported.7 We note that the lowest dose at which dilator effects of PGI2 has been seen on cerebral vessels in vitro6 exceeds both the normal circulating level and that we might expect to attain during an infusion. '0 The blood brain barrier might reduce the effective dose delivered by an intravenous infusion even further.
The effects of PGI2 on blood pressure, pulse and the symptoms experienced by the subjects in the current study were similar to those found in previous work [12] [13] [14] and are discussed in more detail elsewhere. It seems likely that the headache frequently reported during PGI2 infusion is the result of vasodilation occurring in the external carotid circulation (as demonstrated by the facial flush), although the current results do not exclude the possibility that the headache results from changes in the calibre of larger intracranial vessels that are not reflected by alterations in cerebral perfusion.
One possible explanation for the fall in CBF recorded in man lies in the effects of PGI2 elsewhere in the body. The large drop in peripheral resistance during PGI2 infusion is only partly compensated by the rise in cardiac output, '6 '" and a fall in diastolic pressure is usually recorded. PGI2 has a differing effect on the various vascular beds, and it is probable Results during PGI2 compared with saline using paired t tests: * p = < 0 05 t p = < 0 01 t = NS.
group
Effect of epoprostenol (prostacyclin, PGI) on cerebral blood flow in man that the increased cardiac output is directed mostly into vasodilated sphlanchnic and liver blood vessels 8 rather than into muscle,'" renal '9 
